March 7, 2012

The Food and Drug Administration has declined to approve a drug made by Eisai for leukemia in certain elderly patients, the drug maker said.

February 10, 2012

An expert panel at the Food and Drug Administration has given a thumbs-down to a drug made by Astex Pharmaceuticals and Eisai for which the two had sought approval as a treatment for leukemia.

December 20, 2011

The market for drugs to treat ulcerative colitis will increase from 2010's $1.7 billion to $3 billion in 2020, according to a new report by market research firm Decision Resources.

October 11, 2011

The Food and Drug Administration has accepted the first regulatory approval application for a generic version of a cancer drug made by Eisai.

August 30, 2011

A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.

July 29, 2011

The Food and Drug Administration has asked Eisai to redo its regulatory application for a drug to treat epilepsy, Eisai said Friday.

June 7, 2011

Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

June 1, 2011

The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

June 1, 2011

Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

March 4, 2011

The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.

February 18, 2011

SUPPLIER NEWS — Drug maker Valeant Pharmaceuticals International has acquired U.S. and Canadian rights to certain formulations of a GlaxoSmithKline drug used to treat cold sores. Valeant acquired the rights to nonophthalmic topical formulations of Zovirax (acyclovir) from GSK for $300 million through its Canadian subsidiary, Biovail Labs.



February 2, 2011

The Food and Drug Administration declined to approve a drug made by Eisai for treating gastroesophageal reflux disease, Eisai said Tuesday.

January 25, 2011

Eisai will not seek regulatory approval for a drug to treat severe sepsis after getting lackluster results from a late-stage clinical trial, the drug maker said Tuesday.

November 8, 2010

Two drug makers conducting a late-stage clinical trial of a drug for treating overweight and...

October 24, 2010

The Food and Drug Administration declined to approve a regulatory approval application from Arena Pharmaceuticals...

October 4, 2010

Ranbaxy has won the right to sell a generic version of an Alzheimer’s disease drug...

September 26, 2010

Greenstone announced the launch of an authorized generic version of the Alzheimer’s disease drug Aricept...

September 16, 2010

The Food and Drug Administration has accepted for review a regulatory approval application for a...

September 16, 2010

An advisory committee of the Food and Drug Administration has given a thumbs-down to a...

September 7, 2010

The generics division of Pfizer will sell an authorized generic version of a drug used...

July 18, 2010

Eisai's new drug application for a drug designed as an adjunctive treatment of seizures associated...

June 30, 2010

Japanese drug maker Eisai will market a drug in the United States that was developed...

June 29, 2010

Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug...

May 13, 2010

Drug maker Eisai and the Alzheimer’s Association are calling for nominations for the 2010 C.A.R.E....